GLUE
Monte Rosa Therapeutics, Inc.Company with tickers: GLUE
CIK
1826457
CUSIP
61225M102
Shares Outstanding
84,479,418
Website
https://www.monterosatx.com
13F Activity (30d)
7 filings
3 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $54,244,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $44,069,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-50,034,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-44,503,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | — | ||||
| EPS (Diluted) | — |